Update shared on 16 Nov 2025
Fair value Increased 0.71%Electromed's analyst fair value target increased slightly from $35.00 to $35.25, as analysts cite consistent double-digit revenue growth forecasts and improving operational efficiency in recent reports.
Analyst Commentary
Bullish Takeaways- Bullish analysts highlight Electromed's consistent double-digit revenue growth forecasts and note that ongoing top-line expansion is expected in the coming years.
- Recent financial results exceeded expectations, which is viewed as evidence of strong execution and signals continued operational improvement.
- The company is recognized for its market-leading position in the underserved bronchiectasis segment. This suggests there is significant opportunity for further growth.
- Improved operating leverage and a clean balance sheet are seen as key factors that could boost profitability and support higher valuation levels going forward.
What's in the News
- Electromed, Inc. completed a share repurchase of 40,848 shares, representing 0.49 percent, for $1 million between September 9, 2025 and September 30, 2025. This was part of the buyback announced on September 9, 2025 (Key Developments).
- The Board of Directors authorized a new buyback plan on September 9, 2025 (Key Developments).
- Electromed announced a share repurchase program to buy back up to $10 million worth of shares (Key Developments).
- Between April 1, 2025 and May 31, 2025, Electromed completed the repurchase of 160,863 shares, representing 1.89 percent, for $3.55 million. This finalized the $5 million tranche announced on March 10, 2025 (Key Developments).
Valuation Changes
- Consensus Analyst Price Target has increased slightly, moving from $35.00 to $35.25.
- Discount Rate has risen to 7.67 percent from 7.46 percent. This indicates a modest upward adjustment in risk assessment.
- Revenue Growth forecasts have strengthened, climbing from 9.01 percent to 9.85 percent.
- Net Profit Margin estimates have decreased marginally, from 16.04 percent to 15.93 percent.
- Future P/E has fallen appreciably, declining from 26.12x to 22.03x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.